Back to Search
Start Over
ROS enhance angiogenic properties via regulation of NRF2 in tumor endothelial cells.
- Source :
-
Oncotarget [Oncotarget] 2017 Jul 11; Vol. 8 (28), pp. 45484-45495. - Publication Year :
- 2017
-
Abstract
- Reactive oxygen species (ROS) are unstable molecules that activate oxidative stress. Because of the insufficient blood flow in tumors, the tumor microenvironment is often exposed to hypoxic condition and nutrient deprivation, which induces ROS accumulation. We isolated tumor endothelial cells (TECs) and found that they have various abnormalities, although the underlying mechanisms are not fully understood. Here we showed that ROS were accumulated in tumor blood vessels and ROS enhanced TEC migration with upregulation of several angiogenesis related gene expressions. It was also demonstrated that these genes were upregulated by regulation of Nuclear factor erythroid 2-related factor 2 (NRF2). Among these genes, we focused on Biglycan, a small leucine-rich proteoglycan. Inhibition of Toll-like receptors 2 and 4, known BIGLYCAN (BGN) receptors, cancelled the TEC motility stimulated by ROS. ROS inhibited NRF2 expression in TECs but not in NECs, and NRF2 inhibited phosphorylation of SMAD2/3, which activates transcription of BGN. These results indicated that ROS-induced BGN caused the pro-angiogenic phenotype in TECs via NRF2 dysregulation.
- Subjects :
- Biglycan metabolism
Cell Line, Tumor
Cell Movement genetics
Gene Expression Regulation, Neoplastic
Humans
NF-E2-Related Factor 2 metabolism
Neoplasms genetics
Neoplasms metabolism
Neoplasms pathology
Oxidative Stress
Smad2 Protein metabolism
Smad3 Protein metabolism
Endothelial Cells metabolism
NF-E2-Related Factor 2 genetics
Neovascularization, Pathologic genetics
Neovascularization, Pathologic metabolism
Reactive Oxygen Species metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1949-2553
- Volume :
- 8
- Issue :
- 28
- Database :
- MEDLINE
- Journal :
- Oncotarget
- Publication Type :
- Academic Journal
- Accession number :
- 28525375
- Full Text :
- https://doi.org/10.18632/oncotarget.17567